Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CytoSorbents Corporation (OTC:CTSO) is also one not to ignore in the medical device sector, as this company recently announced the official commercial launch of its blood purification CytoSorb device, destined to treat severe sepsis and other indications where high cytokines are present. The device was approved in Europe on results strong enough that European regulators did not even wait for final data to be compiled before rendering their decision. It also helped that CytoSorb targets a market for which there are currently no effective treatments. Additional trials in the US are in the preparatory stages.
The sector is definitely in a buyout mood right now, so keep an eye out for potential targets and play the trading game accordingly. Remember, in this sector price retreats materialize just as quickly as the gains do, so it’s often a wise idea to play some trading shares along with holding onto a core position, should one want to stay along for the ride until a story fully plays out. Using the trading shares to bank some profits along the way when the hype picks up, however, can often leave an investor well on ‘house money’ before the key catalysts take shape.
Happy Trading!!!
http://marketplayground.com/2012/07/10/buyout-talk-catalysts-and-clinical-results-can-move-these-healthcare-stocks-amrn-gsk-hgsi-ilmn-rhhby-amln-bmy-pbth-teva-lptn-pfe-ssh-mric-si-bsx-ctso/#more-23868
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the treatment of
patients with cancer. The Company is developing tesetaxel, a novel, orally
absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel.
As the leading oral taxane in clinical development, tesetaxel has been evaluated
in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials.
The Company has announced that gastric (stomach) cancer will be the lead
indication for registration. Genta is exclusively marketing Ganite(R) (gallium
nitrate injection) in the U.S, which is indicated for treatment of symptomatic
patients with cancer-related hypercalcemia that is resistant to hydration. The
Company has developed proprietary oral formulations of the active ingredient in
Ganite(R) that are being evaluated as potential treatments for diseases
associated with accelerated bone loss. For more information about Genta, please
visit our website at: www.genta.com.
Dr. Robert Melamede, President and CEO of Cannabis Science (CBIS.OB), will be presenting at the XIX International AIDS Conference (AIDS 2012, www.aids2012.org) taking place in Washington, DC from July 22-27, 2012. Over 30,000 policy makers, researchers, clinicians and advocates from across the globe will be attending the world’s largest and premiere HIV/AIDS conference this year, which is being held in the U.S. for the first time in over two decades. CBIS
Dr. Roscoe M. Moore Jr., U.S. Assistant Surgeon General (Retired), Appointed to Cannabis Science Scientific Advisory Board - CBIS
Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA) along with the positions in the US Public Health Service, and most recently, the Office of the US Secretary of Health and Human Services.
Arkansans for Compassionate Care submitted 11,000 pages petitions Thursday containing 67,885 signatures. The secretary of state’s office will spend the next few days making an initial rough count of the signatures gathered by the group.
To earn a spot on the ballot, the group must submit 62,507 signatures from registered voters, which are validated by the secretary of state’s office. Any signatures deemed invalid are thrown out and organizations like Arkansans for Compassionate Care have 30 days to make up the difference. The validation process is expected to take up to ten days.
Arkansas could be the next to legalize medical marijuana. CBIS
. The Company is working as fast as it can to make its cannabis-based formulations that target critical ailments more widely available through multiple regulatory body guidelines. This approach will allow the Company to release its formulations to multiple markets reaching the maximum amount of people in the shortest time frame across the nation and internationally. To support this cause Cannabis Science has been working with numerous patients who have been documenting their self-medicating treatment process using the cannabis-extracts.
The Company continues to receive a large number of inquiries about current and new product releases and operational updates on its projects in the works. The Company is in the process of updating its website to provide up-to-date timeline information on its projects, product lines, events, conferences and other important corporate and operational information for the public as released for the public.
CBIS - The benefits (of moving to) Denver, where the company already has a center, include stable municipal laws, as well as a less suspicious district attorney, according to Stubbs and Melamede.
They aren't wasting time. The scientists estimate the core labs, offices and manufacturing facilities in Denver will be complete by the end of summer.
Once settled in the Denver facility, Stubbs says Cannabis Science will be able to further its research for oral and topical cannabis drugs, with the goal of achieving U.S. Food and Drug Administration approval in MMJ-friendly states. (It's already hired a regulatory group to guide it through the application for phase one FDA clinical trial work.) And it will still offer buds for smoking, edibles and beverages.
Down the road, Stubbs says, the company hopes to have an "affiliate partnership" back in the Springs, as well as in other cities on the Front Range and the Western Slope.
Melamede, a microbiology professor at the University of Colorado at Colorado Springs, feels science is the answer, so he helped create Cannabis Science, a biotech company that develops pharmaceutical cannabis products. The enterprise grew out of the shell of a previous company a year and a half ago, when Melamede took over as president and CEO.
Also at the helm is Chris Stubbs, 27, Cannabis Science's lab director, whose job entails recruiting people for the company's current 20-member team, and helping run the labs. Like all other employees, Stubbs also researches partnerships, including last month's Montana Pain Management acquisition. He says Cannabis Science receives numerous inquiry requests for partnerships. "It's almost too hard to handle right now."
Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Director, Clinical Development HIV, GlaxoSmithKline, UK,
Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA:
Principal Clinical Research Scientist, Antivirals, Glaxo Wellcome, UK and USA:
Senior Clinical Research Scientist, HIV, The Wellcome Foundation, UK
Dr. Bray’s extensive experience in the field of HIV drug development will compliment Cannabis Sciences’ prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitor. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.
“It is highly commendable that Cannabis Science has made a commitment to develop a robust research program to further understand potent effects of cannabinoids on HIV TAT via cannabinoid 2 receptors and to translate these into therapeutically active products against HIV infection” stated Dr. Bray.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
“We are thrilled to welcome Dr. Bray to our Scientific Advisory Board. We are confident that her expertise in HIV research, drug development and marketing, as well her extensive knowledge in the HIV field, will greatly enhance our suburb group of scientific experts as we launch our Cannabinoid HIV TAT inhibitor platform,” states Dr. Robert Melamede, Ph.D. President & CEO Cannabis Science Inc.
CBIS
Most of their shares show to be restricted according to the intro box. If that is true, I don't know how it is being taken down. As you know, I bought at the time the CEO was on stock radio and paid the 52 weeks high.
I'm wondering about the accounting firm filing numbers. It also says the outstanding common stock is 692.
"I am deeply dismayed that the federal government would seek to deprive Californians of this vital medicine," Oakland City Attorney Barbara Parker said in a statement released by her office and read at a news conference held at City Hall by Harborside's owners.
"These actions will force patients into the underground market of street corners and back alleys, undermining public safety and endangering their health and lives," Parker said. CBIS
Q2 was the end of June (2 weeks ago) I think they have another 30 days to get the report out.
The Q2 fins may show more sales due to the trade shows. We'll see. I was looking at NBI website to see if the new product that K Dog saw at Las Vegas was offered. It's not there yet but I will keep checking.
Blessing in a bottle Review by Rev. Russell R. Stevenson , Fallon , Nevada (Posted on 5/2/12)
My wife, Fredda, had been diagnosed with C.O.P.D. four years ago, and has been on oxygen for the last year.
Her mornings and nights were constantly filled with hacking and coughing, shortness of breath to the point I feared she might not be with me in the morning.
The doctors prescribed various powders to breath in, and a nebulizer to help her to breath better, but they hardly had any effect.
While browsing the internet looking for anything that I could find that might help her, I found Nature's Bioceauticals and their Breathing Formula; After reading Mr. Browns review I thought, if this is true, it was worth a try, I was desparate. So I ordered three bottles of the Breathing Formula and upon receiving them, Fredda took three doses a day, and within three weeks we took the oxygen tank back to the medical supply. It's been two months now and no more hacking or coughing {other than normal people do} and I take it too, so we both get a good nights sleep.
I want to thank you folks for this blessing.
The revenue estimate is based on contracts already in place as reported in the PR.
The fact that Dr. Bob Melameade took time out of his busy schedule to answer an e-mail from one of us earns my respect. Of course, he already had my respect but that was above and beyond the call.
EGTK - The semi-trailers are another major step towards fulfilling the agreements signed with two entities in Mostar, whereas Aluminij d.o.o. Mostar, a large manufacturer of aluminum is the major consumer. The contracts are expected to yield revenues of approximately $30,000,000 in the first three years of full operations, with expected total revenues of about $100,000,000.
okoil, welcome as a moderator to EGTK.
Marijuana conspiracy:
The reason for prohibition is not because marijuana is unsafe or ineffective, it is because whole marijuana cannot be patented by drug companies, which pay millions to get their drugs approved, and thus keep the FDA in business.
Prevents Alzheimer’s
In 2006, the Scripps Insitute proved that the THC found in marijuana works to prevent Alzheimer’s by clocking the deposits in the brain that cause the disease.
Treats Glaucoma
Some studies suggest that use of medical marijuana helps lower intraocular pressure in the eyes of glaucoma patients.
Prevents Seizures
Marijuana is a muscle relaxant and has “antispasmodic” qualities which have proven to be very effective treatment of seizures.
Helps Those with ADD & ADHD
A well documented 2009 USC study showed that marijuana is not only a perfect alternative for Ritalin but treats the disorder without any of the negative side effects of the pharmaceuticals. ADHD affects an estimated 4.1% of adults, ages 18 to 44, in a given year.
May Treat Multiple Schlerosis
Marijuana works to stop the neurological effects of muscle spasms that come from multiple sclerosis by protecting nerves from the damage caused by the fatal disease.
http://www.ganjarism.com/marijuana-10-major-health-benefits/
Nitwit, I'm still here. Good to see you.
CBIS is - Like a Phoenix Rising from the Ashes
“Suffering and joy teach us, if we allow them, how to make the leap of empathy, which transports us into the soul and heart of another person. In those transparent moments we know other people’s joys and sorrows, and we care about their concerns as if they were our own.”
~Fritz Williams
AGCZ - Key Highlights:
• Healthy 3:1 asset to debt ratio.
• Andes Gold owns two producing mines and one fully operating mill.
• The mill is currently processing 50 tonnes of ore per day, with a goal of increasing to 100 tonnes by the end of April 2012.
• The capacity of the mill is 170 tonnes per day.
• The average head grade of ore being processed is 1.0 oz gold and 15 g of silver per tonne of ore.
• Andes Gold processes ore from other mines. This increases cash flow and profits.
• On the Miranda vein, the company has over 300,000 oz. of "proven reserves". "Inferred reserves" from the 700 m level on Miranda, Azul, Estrella, Sul and Viscaya veins are 600,000 oz.
• Andes Gold continues to develop existing "reserves" as well as acquire new "reserves".
• Andes Gold is driving innovation in the mining industry by creating its very own definitions for reserves and resources! Every other company is hamstrung by the industry standard CIM definitions. Andes has freed itself from those leg irons and lets the imagination run wild with it's unique definitions of those terms.
• Andes has bugun reclamation programs on its projects.
“We are honored and excited that Dr. Roscoe M. Moore, Jr. is joining the Cannabis Science Scientific Advisory Board as the company enters into further clinical development of a wide range of commercial clinical investigations. His experience and knowledge in the medical field and his background within the FDA and US Public Health Services will be a tremendous asset to Cannabis Science. In addition to overseeing the development of CS-TATI-1, he will assist in our path towards human studies for HIV drug resistance and catabolic cachexia,” commented Dr Melamede. “Dr. Moore’s decision to join Cannabis Science's Scientific Advisory Board emphasizes the potential of phytocannabinod antiviral activity and our strong research and development efforts.” CBIS
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About HIV
HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and is creating a pressing need to develop new HIV drugs.
The U.S. government invests billions of dollars a year in HIV/AIDS research, treatment and care through a variety of programs. The Ryan White CARE Act, which funds the treatment and care of people living with HIV in the U.S., totals $2.3 billion a year. Among its many other contributions to fighting HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S. Military HIV Research Program and approximately $1 billion per year to The Global Fund to Fight AIDS, Tuberculosis and Malaria.
Pharmaceutical sales to treat HIV equal US $10.6 billion annually. Treatment cost per patient in the U.S. for HIV antivirals alone is approximately US $15,000 a year.
CBIS
The Company is working as fast as it can to make its cannabis-based formulations that target critical ailments more widely available through multiple regulatory body guidelines. This approach will allow the Company to release its formulations to multiple markets reaching the maximum amount of people in the shortest time frame across the nation and internationally. To support this cause Cannabis Science has been working with numerous patients who have been documenting their self-medicating treatment process using the cannabis-extracts.
CBIS - Robert Melamede stated, “Every day we are touched by the individual faces of Medical Cannabis patients. From babies to centenarians, peoples are realizing the incredible effectiveness, safety, and broad applicability of cannabis-based medicines. Judge Gustin L. Reichbach is one of many patients confirming and sharing their medical cannabis success stories with the world. As politicians realize that their continuance is office is dependent on their recognition and support of medical marijuana, things will change. A recent demonstration that the times are changing, Rep Nancy Pelosi recently came out in against the anti-medical marijuana assaults, by federal policies and agents, on medical marijuana facilities. All of us at Cannabis Science thank and respect courageous heroes like Gustin L. Reichbach and all patients who share their stories. We encourage others to do likewise as the world wide movement to end cannabis prohibition grows with the volume of the patient’s voice. Additionally we are proud that our Medical Advisory Board member, Dr. Alan Shackelford, has been meeting with legislators in New York and Connecticut to educate, them based on his knowledge and experiences, regarding the medical benefits of the cannabis plant.”
The full editorial may be found here:
http://www.nytimes.com/2012/05/17/opinion/a-judges-plea-for-medical-marijuana.html?_r=2&smid=tw-share
Gustin L. Reichbach’s bio can be found here:
http://www.nycourtsystem.com/applications/judicialdirectory/Bio.php?ID=7023088
CBIS - You can view the patient’s photographs during the treatment process, as well as the full biopsy report from the physician, on the Cannabis Science website www.cannabisscience.com. Click the button “View Images of 2nd Self-Medicated Patient & The Apparent Success” to view the full biopsy report, photos and additional information.
Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, “Squamous cell carcinomas have a much greater invasive potential than is typical of basal cell carcinomas. Photo-documentation of topical cannabis extract treatments of patient #2 and patient #3 dramatically demonstrate how the treatment appear to extrude the subcutaneous tumor to the surface as the killing and subsequent healing proceeds. Patient #3 reports continued progress as his tumors appear to shrink and the pain levels continue to improve. The patient's wife commented that about 75% of the large tumor mass is gone. We will continue with ‘live updates’ as new pictures and physician reports are made available to us.”
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.
quertytrader, thank for reminding us that cannabis science is curing cancer and a lot of other diseases that afflict a great many of our friends and relatives. I'm glad to have you as a moderator to the CBIS board.
Did you just post that some people think that manipulating the market of a particular stock is illegal? That they are being banned?
<;P Hope you had a wonderful 4th. Under a burn ban and a 100+ here. No fireworks. Bummer for the kids.
Jacque, I appreciate your posts. Very good. Keep it up.
Government-sponsored study destroys DEA’s classification of marijuana
AFPW - RECAP from recent NEWS:
Beyond what was reported in the AFPW news release of May 2, 2012, additional industry and government players have now expressed interest in validating the Company's unique hydrogen generation technology to provide a viable new source of hydrogen for these applications. A Non-Disclosure Agreement has just been signed with a major equipment supplier to the wireless telecomm industry, and another one is in process with a major wireless telecomm carrier.
A major aerospace and marine systems company recently completed a survey of "hydrogen on demand" technologies, and concluded that the AlumiFuel system has a lot of potential for commercial undersea vehicle applications.
The Portable Balloon Inflation System (PBIS)-2000 unit has been formally accepted by the U.S. Air Force Special Operations Command following on-site training by a team of the Company's engineers
"We were gratified by the positive response of Air Force Special Operations personnel to the PBIS-2000.
Their universal reaction was that this is a far superior solution to transporting large helium or hydrogen tanks into and out of the field for weather balloon filling and launching activities worldwide."
AlumiFuel Power Submits Specs on New Portable Balloon Inflation System (PBIS)-200 to Air Force Customer
Pilot balloons are the most common weather balloon size for upper air meteorological soundings in the world. The new PBIS-200 system will meet the requirements of global meteorological services, especially those operating in remote areas or in developing nations, including a number of African countries.
The Company's Chief Technology Officer, Mr. John Boyle, said, "We are confident that the new PBIS-200 will meet the unique needs of our Air Force customer as well as those of meteorological users worldwide.
DRAG - Dragon Polymers
Mr. Ty Et Lieu has been appointed to the Board of Directors of the company. Mr. Et Lieu has over 5 years of experience working on various polymer reclamation projects across North America, notably the McKendry Landfill site located near Kingston, Ontario, Canada. Mr. Et Lieu has extensive experience working with polymer recycling companies from Asia where the need for Nylon 6,6 and Polyethylene terephthalate (PET) is high due to the continents important manufacturing sector.
The appointment of Mr. Et Lieu to the Board of Directors is another important step in the right direction for the success of the company.
DRAG - New symbol - formerly BGBV
Dragon Polymers business model focuses on landfill mining of post-industrial polymers, specifically Nylon 6,6 and Polyethylene terephthalate, that have been buried in landfill sites across North America by large chemical company’s between 1975 and 1990.
With growing landfill sites becoming a worldwide problem, landfill reclamation projects provide Dragon Polymers a unique opportunity to assist in rehabilitating our environment, while earning revenue for the company and enhancing shareholder value. The Company will continue to expand its business model to include other reclamation projects of post-industrial polymer fibre throughout North America.
Polymers such as Nylon and Polyethylene terephthalate are petroleum based and therefore have seen a dramatic increase in price over the past 5 years. This increase has led to a boom in the use of recycled polymers, as a replacement for the virgin product. Once these recycled polymers are cleaned and pelletized they are reused in many diverse manufacturing sectors such as the automotive industry, consumer goods and the food and beverages industry.
Nylon-6,6 (PA66) is a semi-crystalline polyamide commonly used in fiber applications such as carpeting, clothing, and tire cord. It is also used as an engineering material in bearings and gears due to its good abrasion resistance and self-lubricating properties.
Polyethylene terephthalate (sometimes written poly(ethylene terephthalate)), commonly abbreviated PET, PETE, or the obsolete PETP or PET-P, is a thermoplastic polymer resin of the polyester family and is used in synthetic fibres; beverage, food and other liquid containers; thermoforming applications; and engineering resins often in combination with glass fiber.
Depending on its processing and thermal history, polyethylene terephthalate may exist both as an amorphous (transparent) and as a semi-crystalline polymer. The semicrystalline material might appear transparent (particle size < 500 nm) or opaque and white (particle size up to a few microns) depending on its crystal structure and particle size. Its monomer (bis-ß-hydroxyterephthalate) can be synthesized by the esterification reaction between terephthalic acid and ethylene glycol with water as a by-product, or by Transesterification reaction between ethylene glycol and dimethyl terephthalate with methanol as a by-product. Polymerization is through a polycondensation reaction of the monomers (done immediately after esterification/transesterification) with water as the by-product.